duloxetine hydrochloride has been researched along with citalopram in 107 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.93) | 18.2507 |
| 2000's | 30 (28.04) | 29.6817 |
| 2010's | 63 (58.88) | 24.3611 |
| 2020's | 13 (12.15) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Leonard, BE | 1 |
| Kranzler, J; Nemeroff, CB; Owens, MJ; Plott, SJ; Rao, SG; Vaishnavi, SN | 1 |
| Angulo, J; Cuevas, B; Cuevas, P; Gupta, S; Sáenz de Tejada, I | 1 |
| Hirschfeld, RM; Vornik, LA | 1 |
| Caccia, S | 1 |
| Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD | 1 |
| Grandoso, L; Pineda, J; Torrecilla, M; Ugedo, L | 1 |
| Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM | 1 |
| Kozian, R | 1 |
| García, L; Grandoso, L; Pineda, J; Ugedo, L | 1 |
| Baker, B; Burt, T; Desta, Z; Flockhart, D; Greenblatt, DJ; Harmatz, JS; Klick-Davis, A; Luo, Y; Perloff, ES; Preskorn, SH | 1 |
| Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM | 1 |
| Dirks, AC; van Hyfte, DM | 1 |
| Detke, MJ; Faries, DE; Mallinckrodt, CH; Meyers, AL; Prakash, A | 1 |
| Aaronson, ST; Arnold, LM; Mallinckrodt, CH; Pigott, TA; Prakash, A; Wohlreich, MM | 1 |
| Florea, I; Gembert, K; Wade, A | 1 |
| Alexopoulos, GS; Bose, A; Gandhi, C; Gommoll, C; Khan, A; Li, D | 1 |
| Clayton, A; Kornstein, S; Mallinckrodt, C; Prakash, A; Wohlreich, M | 1 |
| Detke, MJ; Fava, M; Houston, JP; Mallinckrodt, CH; Prakash, A; Swindle, R | 1 |
| Armstrong, EP; Erder, MH; Malone, DC | 1 |
| Gourion, D | 1 |
| Andersen, HF; Lam, RW; Wade, AG | 1 |
| Danchenko, N; Despiegel, N; Fernández, JL; François, C; Hansen, K; Wade, AG | 1 |
| Andersen, HF; Kilts, CD; Schlaepfer, TE; Wade, AG | 1 |
| Guàrdia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Hinojosa-Calvo, E | 1 |
| Gaynor, PJ; Houston, JP; Katz, MM; Meyers, AL; Prakash, A | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Spadone, C | 1 |
| De Fruyt, J; Demyttenaere, K | 1 |
| Nakayama, K | 1 |
| Andersen, HF; Kornstein, SG; Larsson, S; Li, D; Mao, Y; Papakostas, GI | 1 |
| Guàrdia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Montelongo-Pedraza, P; Padrós Blázquez, F; Peró-Cebollero, M | 1 |
| Crawford, GM; Wade, AG | 1 |
| Despiégel, N; Lam, RW; Lönn, SL | 1 |
| Gómez-Carbajal, L; Gudayol-Ferré, E; Herrera-Abarca, JE; Herrera-Guzmán, D; Herrera-Guzmán, I; Joan, GO; Peña-Olvira, M; Villuendas-González, E | 1 |
| Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C | 1 |
| Dolder, C; Nelson, M; Stump, A | 1 |
| Danchenko, N; Despiegel, N; Maman, K; Marteau, F; Nordström, G | 1 |
| Deshpande, A; Ing, A; Rizo, C; Seeman, N | 1 |
| Locati, E; Pierò, A | 1 |
| Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP | 1 |
| Liu, X; Mullins, CD; Wang, J | 1 |
| Chapman, A; Delivuk, M; Gartlehner, G; Gaynes, BN; Kaminski, A; Thaler, K | 1 |
| George, T; Granger, RE; Hussain, N; Marangell, LB; Raskin, J; Zhao, GW | 1 |
| Bose, A; Li, D; Tsai, J | 1 |
| Abbar, M; Gilaberte, I; Menchón, JM; Neuhauser, D; Papen, R; Pérez, V; Romera, I; Schacht, A; Svanborg, P | 1 |
| Kieser, M; Stucke, K | 1 |
| Binder, EB; Craighead, WE; Cubells, JF; Dunlop, BW; Goodman, MM; Kelley, ME; Kinkead, B; Kutner, M; Mayberg, HS; Nemeroff, CB; Newport, DJ; Owens, MJ; Pace, TW; Ritchie, JC; Rivera, VA; Westen, D | 1 |
| Abbar, M; Gilaberte, I; Menchón, JM; Neuhauser, D; Papen, R; Pérez, V; Picard, H; Romera, I; Schacht, A | 1 |
| Karaiskos, D; Paparrigopoulos, T; Spengos, K; Tzavellas, E; Vassilopoulou, S | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Assisi, AP; Fedullo, F; Gianni, W; Modestino, A; Scuteri, A | 1 |
| Chappell, JC; Detke, M; Haber, H; Kovacs, R; Mitchell, MI; Pangallo, B; Wright, R | 1 |
| Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A | 1 |
| Budac, D; du Jardin, KG; Jensen, JB; Pehrson, AL; Sanchez, C; Smagin, G; Song, D | 1 |
| Chappell, JC; Dean, RA; Detke, MJ; Eisenhofer, G; Haber, H; Iyengar, S; Knadler, MP; Lachno, DR; Lobo, ED; Mitchell, MI; Nemeroff, CB; Owens, MJ; Pangallo, B | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Leiser, SC; Pehrson, AL; Robichaud, PJ; Sanchez, C | 1 |
| Becker, T; Kösters, M; Staudigl, L | 1 |
| Brignone, M; Ereshefsky, L; Francois, C; Lançon, C; Llorca, PM; Rive, B; Salah, S | 1 |
| Dueñas, H; Haro, JM; Hong, J; Moneta, MV; Montgomery, W; Novick, D; Peng, X | 1 |
| Egashira, N; Kuwahara, J; Masuda, S; Ueda, M; Ushio, S; Yamada, T; Zukeyama, N | 1 |
| Papakostas, GI | 1 |
| Creedon, TB; Hodgkin, D; Horgan, CM; Merrick, EL; Stewart, MT | 1 |
| Biglia, N; Bounous, VE; Pecchio, S; Sgro, LG; Susini, T; Torta, R; Tuninetti, V | 1 |
| Citrome, L | 1 |
| Andersen, SE; Gislasson, G; Hansen, AH; Holm, EA; Leth-Møller, KB; Torp-Pedersen, C; Torstensson, M; Ødum, L | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Brawman-Mintzer, O; Dauphin, M; Gao, J; Geibel, B; Madhoo, M; McIntyre, RS; Richards, C; Sambunaris, A; Weisler, R | 1 |
| Bhaumik, R; Crane, NA; Dion, C; Gowins, JR; Jenkins, LM; Langenecker, SA; Mickey, BJ; Zubieta, JK | 1 |
| Chekroud, AM; Gueorguieva, R; Krumholz, HM; Krystal, JH; McCarthy, G; Trivedi, MH | 1 |
| Choi, KS; Craighead, WE; Dunlop, BW; Kelley, ME; Kinkead, B; Mayberg, HS; McGrath, CL; Nemeroff, CB; Rajendra, JK | 1 |
| Aponte-Rivera, V; Craighead, WE; Dunlop, BW; Kelley, ME; Kinkead, B; Mayberg, HS; Mletzko-Crowe, T; Nemeroff, CB; Ritchie, JC | 1 |
| Berlim, M; Chachamovich, E; Fiori, LM; Foster, J; Jollant, F; Kennedy, SH; Lopez, JP; Richard-Devantoy, S; Rotzinger, S; Turecki, G | 1 |
| Fuller, RR; Hughes, S; Lacasse, J; Spaulding-Givens, J | 1 |
| Chen, S; Jiang, H; Jiang, W; Liang, J; Lu, N; Yin, Y; Yuan, Y; Yue, Y; Zhang, Y | 1 |
| Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
| Dubois, T; Jacques, D; Lepiece, B; Reynaert, C; Zdanowicz, N | 1 |
| Johansen, SS; Linnet, K; Nedahl, M | 1 |
| Cole, SP; Craighead, WE; Dunlop, BW; Mayberg, HS; Nemeroff, CB | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Finkelstein, Y; Gomes, T; Juurlink, DN; Li, P; Macdonald, EM; Mamdani, MM | 1 |
| Ajilore, O; Bessette, KL; Crane, NA; DelDonno, SR; Hsu, DT; Klumpp, H; Langenecker, SA; Leow, A; Mickey, BJ; Peters, AT; Phan, KL; Ransom, MT; Shankman, SA; Stange, JP; Walker, SJ; Zubieta, JK | 1 |
| Binder, EB; Carrillo-Roa, T; Craighead, WE; Dunlop, BW; Kelley, ME; Kutner, MH; Lori, A; Mayberg, HS; Nemeroff, CB; Rivera, VA | 1 |
| Buchanan, GF; Dayton, KG; Kruse, SW; Purnell, BS; Rosner, JI | 1 |
| Cole, SP; Craighead, WE; Dunlop, BW; Kinkead, B; LoParo, D; Mayberg, HS; Mletzko-Crowe, T; Nemeroff, CB | 1 |
| Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D | 1 |
| Aytes, KL; McGrane, IR; Morefield, CM | 1 |
| Alag, P; Balasubramaniam, M; Gupta, A; Gupta, S; Joshi, P; Maher, S; Tampi, D; Tampi, RR; Young, J | 1 |
| Sourdeau, A; Zdanowicz, N | 1 |
| Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Yokoi, Y; Yoshimura, N | 1 |
| Holper, L | 1 |
| Furukawa, TA; Imai, H; Noma, H | 1 |
| Bayraktaroglu, Z; Cankaya, S; Ergun, T; Hanoglu, L; Lakadamyali, H; Oktem, EO; Ozsimsek, A; Saatçi, Ö; Uykur, AB; Velioglu, HA; Yıldız, S; Yulug, B | 1 |
| Abe, T; Furukawa, TA; Iwanami, A; Mimura, M; Nakagawa, A; Nakagome, K; Nishioka, G; Tani, M; Watanabe, K; Yokoi, Y; Yoshimura, N | 1 |
| Chapman, A; Gartlehner, G; Gaynes, BN; Nussbaumer-Streit, B; Probst, T; Sönnichsen, A; Thaler, K; Winkler, D | 1 |
| Bonci, A; Marino, RAM; McDevitt, RA; Tejeda, HA | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Haas, DM; Marks, C; Quinney, SK; Silvola, R; Teal, E | 1 |
| Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A | 1 |
| Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S | 1 |
| Bracke, F; Frieling, H; Leffler, A | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Asadi-Pooya, AA; Firouzabadi, N; Kashkooli, M; Malekpour, M; Zamiri, B | 1 |
25 review(s) available for duloxetine hydrochloride and citalopram
| Article | Year |
|---|---|
New approaches to the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Brain; Bupropion; Citalopram; Cyclohexanols; Depressive Disorder; Dopamine; Duloxetine Hydrochloride; Humans; Receptors, Dopamine; Receptors, GABA; Receptors, Neurotransmitter; Receptors, Serotonin; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 1996 |
Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Topics: Citalopram; Depressive Disorder; Double-Blind Method; Duloxetine Hydrochloride; Humans; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2004 |
Metabolism of the newest antidepressants: comparisons with related predecessors.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Duloxetine Hydrochloride; Humans; Pyrimidines; Serotonin Receptor Agonists; Thiophenes | 2004 |
[Antidepressants and their onset of action: a major clinical, methodological and pronostical issue].
Topics: Affect; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Mianserin; Mirtazapine; Patient Satisfaction; Personality Inventory; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Suicide Prevention; Thiophenes; Time Factors; Treatment Refusal; Venlafaxine Hydrochloride | 2008 |
Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2008 |
[Severe forms of depression: the efficacy of escitalopram].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Quality of life measurement in antidepressant trials. Is there an added value?
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Duloxetine Hydrochloride; Humans; Personality Inventory; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiophenes | 2009 |
[Mechanism of action of new generation antidepressants under development in Japan: focusing on dopamine neurotransmission].
Topics: Antidepressive Agents; Citalopram; Dopamine; Duloxetine Hydrochloride; Humans; Japan; Mianserin; Mirtazapine; Synaptic Transmission; Thiophenes | 2009 |
Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Time Factors; Venlafaxine Hydrochloride; Young Adult | 2009 |
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Norepinephrine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2010 |
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
Topics: Aged; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Drug Interactions; Duloxetine Hydrochloride; Humans; Thiophenes | 2010 |
Second-generation antidepressants for seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Phototherapy; Randomized Controlled Trials as Topic; Reboxetine; Seasonal Affective Disorder; Thiophenes | 2011 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
[If the general practitioner has to decide: what is the evidence for the selection of antidepressants?].
Topics: Acetamides; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Duloxetine Hydrochloride; Evidence-Based Medicine; General Practice; Germany; Guideline Adherence; Humans; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
Topics: Acetamides; Adult; Aged; Antidepressive Agents; Benzofurans; Citalopram; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Humans; Hypnotics and Sedatives; Indoles; Male; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Thiophenes; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2014 |
Antidepressants and their effect on cognition in major depressive disorder.
Topics: Adult; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Executive Function; Humans; Middle Aged; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sulfides; Vortioxetine | 2015 |
Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Vilazodone Hydrochloride | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Antidepressants for anxiety disorders in late-life: A systematic review.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Duloxetine Hydrochloride; Humans; Late Onset Disorders; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Second-generation antidepressants for treatment of seasonal affective disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Bias; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Observational Studies as Topic; Phototherapy; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Reboxetine; Seasonal Affective Disorder; Thiophenes; Treatment Outcome | 2021 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
37 trial(s) available for duloxetine hydrochloride and citalopram
| Article | Year |
|---|---|
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.
Topics: Adult; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2D6; Drug Interactions; Duloxetine Hydrochloride; Female; Humans; Male; Metoprolol; Middle Aged; Reference Values; Sertraline; Single-Blind Method; Thiophenes | 2007 |
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Method; Duloxetine Hydrochloride; Erectile Dysfunction; Female; Gastrointestinal Diseases; Humans; Irritable Mood; Male; Middle Aged; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome; Xerostomia | 2007 |
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Placebos; Remission Induction; Thiophenes; Treatment Outcome | 2007 |
A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Tolerance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Thiophenes | 2007 |
Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes | 2007 |
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Behavior; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Thiophenes | 2007 |
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Topics: Absenteeism; Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Sick Leave; Surveys and Questionnaires; Thiophenes; United Kingdom; Young Adult | 2008 |
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Thiophenes; Treatment Outcome | 2009 |
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Citalopram; Cognition; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Male; Memory; Neuropsychological Tests; Neurotransmitter Uptake Inhibitors; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thinking; Thiophenes | 2009 |
Early symptom change prediction of remission in depression treatment.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2009 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine.
Topics: Aged; Citalopram; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Thiophenes; Urination; Urination Disorders | 2010 |
Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain.
Topics: Adult; Aged; Chronic Disease; Citalopram; Duloxetine Hydrochloride; Female; Health Surveys; Humans; Low Back Pain; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2010 |
An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Anxiety Disorders; Citalopram; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Dropouts; Personality Disorders; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2011 |
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Neurotransmitter Uptake Inhibitors; Norepinephrine; Remission Induction; Serotonin; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2011 |
Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
Topics: Adult; Aged; Analysis of Variance; Apathy; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dopamine Uptake Inhibitors; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Severity of Illness Index; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Early switch strategy in patients with major depressive disorder: a double-blind, randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Thiophenes | 2012 |
Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Biomarkers; Brain; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Genetic Testing; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Personality; Predictive Value of Tests; Remission Induction; Research Design; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Substitution; Duloxetine Hydrochloride; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Pain; Pain Measurement; Thiophenes; Treatment Outcome; Young Adult | 2012 |
Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
Topics: Activities of Daily Living; Adult; Aged; Antidepressive Agents; Anxiety; Citalopram; Depression; Duloxetine Hydrochloride; Fatigue; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Sertraline; Stroke; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2012 |
Depression treatment selectively modifies arterial stiffness in older participants.
Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Citalopram; Depression; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Pulse Wave Analysis; Thiophenes; Treatment Outcome; Vascular Stiffness | 2013 |
Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: a mechanistic study using heart rate variability as a pharmacodynamic measure.
Topics: Adrenergic Uptake Inhibitors; Aged; Citalopram; Cross-Over Studies; Duloxetine Hydrochloride; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Thiophenes | 2013 |
Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; California; Central Nervous System; Citalopram; Cross-Over Studies; Duloxetine Hydrochloride; Female; Healthy Volunteers; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Texas; Thiophenes; Young Adult | 2014 |
Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Breast Neoplasms; Cancer Survivors; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Hot Flashes; Humans; Medication Adherence; Middle Aged; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Tablets; Treatment Outcome | 2018 |
Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Least-Squares Analysis; Lisdexamfetamine Dimesylate; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dominance, Cerebral; Duloxetine Hydrochloride; Female; Gyrus Cinguli; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Outcome Assessment, Health Care; Prefrontal Cortex; Psychiatric Status Rating Scales; Young Adult | 2017 |
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Preference; Psychiatric Status Rating Scales; Psychometrics; Treatment Outcome | 2017 |
Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Topics: Antidepressive Agents; Biomarkers; Citalopram; Clinical Decision-Making; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Humans; MicroRNAs; Psychiatric Status Rating Scales; ROC Curve; Treatment Outcome | 2017 |
Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder.
Topics: Antidepressive Agents; Aspirin; Citalopram; Cyclooxygenase Inhibitors; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Selective Serotonin Reuptake Inhibitors | 2017 |
Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Duloxetine Hydrochloride; Female; Humans; Male; Treatment Failure | 2019 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Antidepressive Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2019 |
The therapeutic alliance - its impact on antidepressant therapies in major depressive conditions and on the overall health.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Health Status; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Therapeutic Alliance | 2019 |
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: Study protocol for a randomized, parallel-group, non-inferiority trial.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Equivalence Trials as Topic; Humans; Outpatients | 2019 |
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial.
Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Japan; Outpatients; Treatment Outcome | 2021 |
45 other study(ies) available for duloxetine hydrochloride and citalopram
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Carrier Proteins; Citalopram; Cyclohexanols; Cyclopropanes; Duloxetine Hydrochloride; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Mental Disorders; Milnacipran; Nerve Tissue Proteins; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Symporters; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Blood Vessels; Citalopram; Cyclohexanols; Drug Interactions; Duloxetine Hydrochloride; Female; Nitric Oxide; Norepinephrine; Paroxetine; Phentolamine; Rabbits; Regional Blood Flow; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Vagina; Vasodilation; Venlafaxine Hydrochloride | 2004 |
Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
Topics: Acute Disease; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Disease Models, Animal; Duloxetine Hydrochloride; Male; Mianserin; Mirtazapine; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; Thiophenes | 2005 |
alpha(2)-Adrenoceptor involvement in the in vitro inhibitory effect of citalopram on a subpopulation of rat locus coeruleus neurons.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amphetamines; Animals; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Citalopram; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Idazoxan; In Vitro Techniques; Locus Coeruleus; Male; Methiothepin; Naloxone; Narcotic Antagonists; Neurons; Norepinephrine; Oxazines; Piperazines; Piperidines; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Thiophenes | 2005 |
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
[Brief case report. Duloxetine in Cotard syndrome].
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Delusions; Depersonalization; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Long-Term Care; Olanzapine; Risperidone; Syndrome; Thiophenes | 2005 |
Acute and long-term administration of citalopram desensitizes alpha2-adrenoceptors in the rat vas deferens.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Brimonidine Tartrate; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Duloxetine Hydrochloride; Electric Stimulation; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Thiophenes; Vas Deferens | 2006 |
Recurrent hyponatremia after substitution of citalopram with duloxetine.
Topics: Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depression; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Nortriptyline; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes | 2007 |
Simple options for improving signal detection in antidepressant clinical trials.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Likelihood Functions; Models, Statistical; Paroxetine; Personality Inventory; Placebo Effect; Psychometrics; Reproducibility of Results; Research Design; Signal Detection, Psychological; Thiophenes; Treatment Outcome | 2007 |
A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Duloxetine Hydrochloride; Humans; Markov Chains; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thiophenes; Treatment Outcome; United States | 2008 |
Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition Disorders; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Reference Values; Selective Serotonin Reuptake Inhibitors; Thiophenes; Wechsler Scales | 2010 |
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivity; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Executive Function; Female; Humans; Male; Neuropsychological Tests; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2010 |
Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Decision Support Techniques; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Markov Chains; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recurrence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sweden; Thiophenes; Venlafaxine Hydrochloride | 2010 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Collection; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Fatigue; Fluvoxamine; Humans; Internet; Lethargy; Mianserin; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Stages; Thiophenes; Venlafaxine Hydrochloride | 2011 |
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Topics: Adolescent; Adult; Algorithms; Antidepressive Agents; Chronic Disease; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dosage Forms; Duloxetine Hydrochloride; Female; Humans; Male; Medication Adherence; Middle Aged; Pain; Retrospective Studies; Somatoform Disorders; Thiophenes; Venlafaxine Hydrochloride; Young Adult | 2011 |
A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Likelihood Functions; Multiple Sclerosis, Relapsing-Remitting; Placebos; Poisson Distribution; Randomized Controlled Trials as Topic; Research Design; Sample Size; Therapeutic Equivalency; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.
Topics: 5-Hydroxytryptophan; Animals; Carbidopa; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Exploratory Behavior; Female; Hippocampus; Maze Learning; Memory Disorders; Phenylalanine; Piperazines; Protein Binding; Rats; Rats, Long-Evans; Recognition, Psychology; Selective Serotonin Reuptake Inhibitors; Serotonin; Sulfides; Thiophenes; Vortioxetine | 2014 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Electroencephalography; Frontal Lobe; Male; Piperazines; Rats, Sprague-Dawley; Receptors, Serotonin; RNA-Binding Proteins; Sulfides; Thiophenes; Vortioxetine; Wakefulness | 2014 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Pain; Paroxetine; Prospective Studies; Quality of Life; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 2016 |
Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Citalopram; Cyclopropanes; Duloxetine Hydrochloride; Fluvoxamine; Hep G2 Cells; Humans; Liver Neoplasms; Milnacipran; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline | 2015 |
Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
Topics: Antidepressive Agents; Citalopram; Cost Control; Cost Sharing; Desvenlafaxine Succinate; Drug Costs; Drug Utilization; Duloxetine Hydrochloride; Fluvoxamine; For-Profit Insurance Plans; Health Care Surveys; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Preferred Provider Organizations; Private Sector; Selegiline; United States; Venlafaxine Hydrochloride | 2015 |
Antidepressants and the risk of hyponatremia: a Danish register-based population study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Citalopram; Clomipramine; Denmark; Duloxetine Hydrochloride; Female; Humans; Hyponatremia; Incidence; Male; Mianserin; Middle Aged; Mirtazapine; Registries; Retrospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sodium; Venlafaxine Hydrochloride | 2016 |
Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI.
Topics: Adult; Antidepressive Agents; Citalopram; Cognition Disorders; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Oxygen; Predictive Value of Tests; Treatment Outcome | 2017 |
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents; Bupropion; Citalopram; Cluster Analysis; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Randomized Controlled Trials as Topic; Sleep; Syndrome; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2017 |
Adverse effects and treatment satisfaction among online users of four antidepressants.
Topics: Affective Symptoms; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Humans; Internet; Mental Disorders; Patient Satisfaction; Piperazines; Sulfides; Vilazodone Hydrochloride; Vortioxetine | 2017 |
Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Growth Factors; Outcome Assessment, Health Care | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |
Reference Brain/Blood Concentrations of Citalopram, Duloxetine, Mirtazapine and Sertraline.
Topics: Antidepressive Agents; Brain; Calibration; Cause of Death; Chromatography, Liquid; Citalopram; Drug Overdose; Duloxetine Hydrochloride; Forensic Toxicology; Humans; Linear Models; Mianserin; Mirtazapine; Reference Standards; Reproducibility of Results; Sertraline; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2018 |
Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Duloxetine Hydrochloride; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2018 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
Second-generation anti-depressants and risk of new-onset seizures in the elderly.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Odds Ratio; Ontario; Population; Seizures | 2018 |
Multidimensional imaging techniques for prediction of treatment response in major depressive disorder.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroimaging; Photic Stimulation; Predictive Value of Tests; Psychomotor Performance; Treatment Outcome | 2019 |
Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
Topics: Adult; Aged; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cognitive Behavioral Therapy; Depressive Disorder, Major; Disease Progression; Duloxetine Hydrochloride; Female; Humans; Latent Class Analysis; Male; Middle Aged; Receptor, Serotonin, 5-HT2A; Receptors, Kainic Acid; Serotonin Plasma Membrane Transport Proteins; Tacrolimus Binding Proteins; Treatment Outcome; Young Adult | 2018 |
Effect of monoamine reuptake inhibition and α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Citalopram; Duloxetine Hydrochloride; Electroshock; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Reboxetine; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Sudden Unexpected Death in Epilepsy | 2019 |
Probable Galactorrhea Associated with Sequential Trials of Escitalopram and Duloxetine in an Adolescent Female.
Topics: Adolescent; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Female; Galactorrhea; Humans; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted | 2019 |
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity.
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2020 |
Topological network mechanisms of clinical response to antidepressant treatment in drug-naive major depressive disorder.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Nerve Net | 2021 |
Serotonergic inhibition of responding for conditioned but not primary reinforcers.
Topics: Animals; Citalopram; Conditioning, Classical; Cues; Dorsal Raphe Nucleus; Duloxetine Hydrochloride; Female; Fluoxetine; Gene Knockout Techniques; Male; Mice; Mice, Inbred C57BL; Motivation; Neurons; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin; Tryptophan Hydroxylase | 2021 |
Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study.
Topics: Antidepressive Agents; Bupropion; Citalopram; Duloxetine Hydrochloride; Escitalopram; Female; Fluoxetine; Humans; Infant, Newborn; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
Topics: Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
Antidepressants Are Poor Inhibitors of Heat-Evoked Ion Currents Mediated by TRPM2.
Topics: Adenosine Diphosphate Ribose; Amitriptyline; Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Fluoxetine; HEK293 Cells; Hot Temperature; Humans; Ketamine; Lidocaine; Mice; Paroxetine; Pregabalin; Sertraline; TRPM Cation Channels | 2022 |
FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders: An in-silico study.
Topics: Citalopram; Clomipramine; Duloxetine Hydrochloride; Fluoxetine; Humans; Sertraline; United States | 2023 |